158 related articles for article (PubMed ID: 12920164)
1. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems.
Salonen JS; Nyman L; Boobis AR; Edwards RJ; Watts P; Lake BG; Price RJ; Renwick AB; Gómez-Lechón MJ; Castell JV; Ingelman-Sundberg M; Hidestrand M; Guillouzo A; Corcos L; Goldfarb PS; Lewis DF; Taavitsainen P; Pelkonen O
Drug Metab Dispos; 2003 Sep; 31(9):1093-102. PubMed ID: 12920164
[TBL] [Abstract][Full Text] [Related]
2. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.
Zhang D; Wang L; Chandrasena G; Ma L; Zhu M; Zhang H; Davis CD; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):139-49. PubMed ID: 17062778
[TBL] [Abstract][Full Text] [Related]
3. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
Hidestrand M; Oscarson M; Salonen JS; Nyman L; Pelkonen O; Turpeinen M; Ingelman-Sundberg M
Drug Metab Dispos; 2001 Nov; 29(11):1480-4. PubMed ID: 11602525
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
Stringer RA; Strain-Damerell C; Nicklin P; Houston JB
Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
[TBL] [Abstract][Full Text] [Related]
5. An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant.
Andersson TB; Sjöberg H; Hoffmann KJ; Boobis AR; Watts P; Edwards RJ; Lake BG; Price RJ; Renwick AB; Gómez-Lechón MJ; Castell JV; Ingelman-Sundberg M; Hidestrand M; Goldfarb PS; Lewis DF; Corcos L; Guillouzo A; Taavitsainen P; Pelkonen O
Drug Metab Dispos; 2001 May; 29(5):712-20. PubMed ID: 11302938
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine.
Arbus C; Benyamina A; Llorca PM; Baylé F; Bromet N; Massiere F; Garay RP; Hameg A
Eur J Pharm Sci; 2007 Dec; 32(4-5):357-66. PubMed ID: 17951033
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes.
Cherstniakova SA; Bi D; Fuller DR; Mojsiak JZ; Collins JM; Cantilena LR
Drug Metab Dispos; 2001 Sep; 29(9):1216-20. PubMed ID: 11502731
[TBL] [Abstract][Full Text] [Related]
8. Validated assays for human cytochrome P450 activities.
Walsky RL; Obach RS
Drug Metab Dispos; 2004 Jun; 32(6):647-60. PubMed ID: 15155557
[TBL] [Abstract][Full Text] [Related]
9. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes.
Fang J; McKay G; Song J; Remillrd A; Li X; Midha K
Drug Metab Dispos; 2001 Dec; 29(12):1638-43. PubMed ID: 11717183
[TBL] [Abstract][Full Text] [Related]
10. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue.
Kuperman AV; Kalgutkar AS; Marfat A; Chambers RJ; Liston TE
Drug Metab Dispos; 2001 Nov; 29(11):1403-9. PubMed ID: 11602515
[TBL] [Abstract][Full Text] [Related]
12. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Taavitsainen P; Anttila M; Nyman L; Karnani H; Salonen JS; Pelkonen O
Pharmacol Toxicol; 2000 May; 86(5):215-21. PubMed ID: 10862503
[TBL] [Abstract][Full Text] [Related]
13. CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes.
Davies BJ; Coller JK; Somogyi AA; Milne RW; Sallustio BC
Drug Metab Dispos; 2007 Jan; 35(1):128-38. PubMed ID: 17050648
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) by human liver microsomes: characterization of metabolic pathways and of cytochrome P450 isoforms involved.
Baek MS; Kim JY; Myung SW; Yim YH; Jeong JH; Kim DH
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):381-8. PubMed ID: 11259320
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the cytochrome P450 enzymes and enzyme kinetic parameters for metabolism of BVT.2938 using different in vitro systems.
Baranczewski P; Edlund PO; Postlind H
J Pharm Biomed Anal; 2006 Mar; 40(5):1121-30. PubMed ID: 16307862
[TBL] [Abstract][Full Text] [Related]
16. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation.
Akutsu T; Kobayashi K; Sakurada K; Ikegaya H; Furihata T; Chiba K
Drug Metab Dispos; 2007 Jan; 35(1):72-8. PubMed ID: 17020955
[TBL] [Abstract][Full Text] [Related]
17. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay.
Turpeinen M; Uusitalo J; Jalonen J; Pelkonen O
Eur J Pharm Sci; 2005 Jan; 24(1):123-32. PubMed ID: 15626586
[TBL] [Abstract][Full Text] [Related]
18. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.
Benetton SA; Fang C; Yang YO; Alok R; Year M; Lin CC; Yeh LT
Drug Metab Pharmacokinet; 2007 Apr; 22(2):78-87. PubMed ID: 17495414
[TBL] [Abstract][Full Text] [Related]
19. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers.
Meyer MR; Peters FT; Maurer HH
Drug Metab Dispos; 2008 Nov; 36(11):2345-54. PubMed ID: 18725511
[TBL] [Abstract][Full Text] [Related]
20. Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone.
Kitamura A; Mizuno Y; Natsui K; Yabuki M; Komuro S; Kanamaru H
Biopharm Drug Dispos; 2005 Mar; 26(2):59-65. PubMed ID: 15619261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
